Aspire Biopharma Holdings (ASBP) Cash from Investing Activities (2022 - 2023)
Aspire Biopharma Holdings' (ASBP) quarterly Cash from Investing Activities came in at $632968.0 in Q3 2023, up 100.21% on a QoQ basis from -$294.7 million in Q1 2022.
Aspire Biopharma Holdings (ASBP) Cash from Investing Activities (2022 - 2023) Analysis & Trends
Aspire Biopharma Holdings (ASBP) has 2 years of Cash from Investing Activities data on file, last reported at $632968.0 in Q3 2023.
- On a quarterly basis, Cash from Investing Activities changed N/A year-over-year to $632968.0 in Q3 2023; TTM through Dec 2023 was $632968.0, a 100.21% increase from a year earlier, with the FY2024 full-year figure at $13.8 million, down 95.16% from the prior year.
- Cash from Investing Activities for Q3 2023 stood at $632968.0, up from -$294.7 million in the prior quarter.
- Over the last five years, Cash from Investing Activities for ASBP reached as high as $632968.0 in Q3 2023 and fell as low as -$294.7 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | -45.51 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | -431.90 Mn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | -428.90 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | 172.62 Mn |
| 10 | Aspire Biopharma Holdings | 1.09 Mn | -733,865.14 | 5,750.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2023 | 632,968.00 |
| Sep 30, 2023 | 632,968.00 |
| Mar 31, 2022 | -294.69 Mn |
| Mar 31, 2022 | -294.69 Mn |